The objective of this study was to determine the effect of oral losartan on
the degree of mitral regurgitation (MR), The regurgitant volume and effect
ive regurgitant orifice were quantified using 3 methods (flow convergence,
quantitative Doppler, and quantitative 9-dimensional echocardiography) in 3
2 patients (26 men, mean age 67 +/-14 years) with MR, both at baseline and
4 hours after losartan (50 mg orally). Twenty-eight patients were also reev
aluated after 1 month of continued treatment with losartan (50 mg/day). Wit
h treatment, systolic blood pressure decreased from 143 +/- 16 to 130 +/- 1
8 mm Hg and left ventricular end-systolic wall stress from 173 +/- 46 to 15
6 +/- 44 g/cm(2) (both p <0.001). With treatment, regurgitant volume decrea
sed (from 77 +/- 28 to 64 +/- 26 mi, -18 +/- 10%; p <0.001) in direct relat
ion to the effective regurgitant orifice change (from 43 +/- 16 to 37 +/- 1
5 mm(2), -17 +/- 10%; p <0.001) but without significant change in regurgita
nt gradient or duration. Wide individual variability in response was observ
ed unrelated to the magnitude of blood pressure changes. Larger reduction i
n regurgitant volume was observed in patients with a marked decrease in wal
l stress (r = 0.47, p = 0.01) and higher baseline end-diastolic volume inde
x (r = -0.38, p = 0.03) and regurgitant volume (r = -0.45, p = 0.01), Acute
improvements were sustained and unchanged at 1 month (all p >0.15). Treatm
ent of MR using the angiotensin receptor antagonist losartan produces a sig
nificant and sustained decrease in the degree of MR, with decreases in regu
rgitant volume and effective regurgitant orifice, However, the changes are
of modest and variable magnitude, (C) 2001 by Excerpta Medica, Inc.